<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882150</url>
  </required_header>
  <id_info>
    <org_study_id>IM038-008</org_study_id>
    <nct_id>NCT04882150</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986196 in Healthy Participants Including an Open-label Assessment of Food and Formulation Effects on the Relative Bioavailability of BMS-986196</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, drug levels and drug&#xD;
      effects of BMS-986196 in healthy participants. In addition, an evaluation of food and&#xD;
      formulation effects on BMS-986196 absorption will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 12, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of AEs</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Causality of AEs</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 59 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of SAEs</measure>
    <time_frame>Up to 59 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Causality of SAEs</measure>
    <time_frame>Up to 59 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in weight</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in physical examination</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: QT interval</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in ECG parameters: HR</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Hematology tests</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Clinical chemistry tests</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Coagulation tests</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests</measure>
    <time_frame>Up to 24 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD = single ascending dose. Each participant will receive a single dose of BMS-986196 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD = multiple ascending dose. Each participant will receive multiple doses of BMS-986196 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: FE/Formul.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FE/Formul. = food and formulation effects and relative absorption. Participants will receive two formulations of BMS-986196 (solution and suspension), each formulation with and without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986196</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_label>Part B: MAD</arm_group_label>
    <arm_group_label>Part C: FE/Formul.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A: SAD</arm_group_label>
    <arm_group_label>Part B: MAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Women not of childbearing potential and men, ages 18 or local age of majority to 55&#xD;
             years, inclusive&#xD;
&#xD;
          -  Healthy male and female non-Japanese participants without clinically significant&#xD;
             deviation from normal in medical history, physical examination, electrocardiogram&#xD;
             (ECG), and clinical laboratory determinations&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to 32 kg/m2, inclusive, and total body weight â‰¥ 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected autoimmune disorder, including but not limited to rheumatoid&#xD;
             arthritis, fibromyalgia, systemic lupus erythematosus, polymyalgia rheumatica, giant&#xD;
             cell arteritis, Behcet's disease, dermatomyositis, MS, moderate to severe asthma, any&#xD;
             autoimmune vasculitis, autoimmune hepatitis, or any other active autoimmune disease&#xD;
             for which a participant requires medical follow-up or medical treatment&#xD;
&#xD;
          -  Any history of known or suspected congenital or acquired immunodeficiency state or&#xD;
             condition that would compromise the participant's immune status&#xD;
&#xD;
          -  Presence of any factors that would predispose the participant to develop infection&#xD;
&#xD;
          -  A history of bacterial or fungal meningitis within 1 year prior to screening&#xD;
&#xD;
          -  A history of intracranial or intraspinal bleeding&#xD;
&#xD;
          -  Known intracranial space-occupying mass, including meningioma&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Millcreek</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>BMS-986196</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

